Form 4: Rapport Therapeutics CFO Acquires Stock Options
SEC Form 4 Filing
Troy A. Ignelzi, CFO of Rapport Therapeutics, acquired stock options for 81,366 shares on June 6, 2024, according to a Form 4 filing.
Summary
- Troy A. Ignelzi, the Chief Financial Officer of Rapport Therapeutics, acquired stock options on June 6, 2024.
- The options grant him the right to buy 81,366 shares of Rapport Therapeutics common stock at an exercise price of $17.
- 25% of the shares underlying the option will vest on June 6, 2025, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continued service.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard insider transaction filing. The vesting schedule suggests a long-term commitment from the CFO.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with shareholder interests.
Stakeholder Impact
- The acquisition of stock options by the CFO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of stock option acquisition |
| 06/06/2025 | Date when 25% of the stock options vest |
| 06/05/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.